Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

289 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
Morita A, Strober B, Burden AD, Choon SE, Anadkat MJ, Marrakchi S, Tsai TF, Gordon KB, Thaçi D, Zheng M, Hu N, Haeufel T, Thoma C, Lebwohl MG. Morita A, et al. Among authors: thoma c. Lancet. 2023 Oct 28;402(10412):1541-1551. doi: 10.1016/S0140-6736(23)01378-8. Epub 2023 Sep 19. Lancet. 2023. PMID: 37738999 Clinical Trial.
Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double-blind, placebo-controlled Effisayil™ 1 study.
Morita A, Tsai TF, Yee EYW, Okubo Y, Imafuku S, Zheng M, Li L, Quaresma M, Thoma C, Choon SE. Morita A, et al. Among authors: thoma c. J Dermatol. 2023 Feb;50(2):183-194. doi: 10.1111/1346-8138.16609. Epub 2022 Oct 25. J Dermatol. 2023. PMID: 36282833 Free PMC article. Clinical Trial.
Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis.
Morita A, Choon SE, Bachelez H, Anadkat MJ, Marrakchi S, Zheng M, Tsai TF, Turki H, Hua H, Rajeswari S, Thoma C, Burden AD. Morita A, et al. Among authors: thoma c. Dermatol Ther (Heidelb). 2023 Jan;13(1):347-359. doi: 10.1007/s13555-022-00835-6. Epub 2022 Nov 5. Dermatol Ther (Heidelb). 2023. PMID: 36333618 Free PMC article.
Assessment of the Pharmacokinetics and Safety of Spesolimab, a Humanised Anti-interleukin-36 Receptor Monoclonal Antibody, in Healthy Non-Japanese and Japanese Subjects: Results from Phase I Clinical Studies.
Joseph D, Thoma C, Haeufel T, Li X. Joseph D, et al. Among authors: thoma c. Clin Pharmacokinet. 2022 Dec;61(12):1771-1787. doi: 10.1007/s40262-022-01176-5. Epub 2022 Dec 1. Clin Pharmacokinet. 2022. PMID: 36451029 Free PMC article. Clinical Trial.
Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA) and generalized pustular psoriasis area and severity index (GPPASI).
Burden AD, Bissonnette R, Lebwohl MG, Gloede T, Anatchkova M, Budhiarso I, Hu N, Thoma C, Skalicky AM, Bachelez H. Burden AD, et al. Among authors: thoma c. J Eur Acad Dermatol Venereol. 2023 Jul;37(7):1327-1335. doi: 10.1111/jdv.18999. Epub 2023 Mar 18. J Eur Acad Dermatol Venereol. 2023. PMID: 36854864
Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study.
Elewski BE, Lebwohl MG, Anadkat MJ, Barker J, Ghoreschi K, Imafuku S, Mrowietz U, Li L, Quaresma M, Thoma C, Bachelez H. Elewski BE, et al. Among authors: thoma c. J Am Acad Dermatol. 2023 Jul;89(1):36-44. doi: 10.1016/j.jaad.2023.02.040. Epub 2023 Mar 2. J Am Acad Dermatol. 2023. PMID: 36870370 Free article. Clinical Trial.
The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activity.
Burden AD, Bachelez H, Choon SE, Marrakchi S, Tsai TF, Turki H, Morita A, Lebwohl MG, Bissonnette R, Zheng M, Anadkat MJ, Navarini AA, Tang M, Thoma C, Duffin KC. Burden AD, et al. Among authors: thoma c. Br J Dermatol. 2023 Jul 7;189(1):138-140. doi: 10.1093/bjd/ljad071. Br J Dermatol. 2023. PMID: 37075220 No abstract available.
289 results